Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexMale
• Healthy volunteersNo

You may be able to join if

• Histologically confirmed adenocarcinoma of the prostate.
• High-risk localized prostate cancer, defined as ≥1 of the following (per National Comprehensive Cancer Network or D'Amico criteria):
• Prostate specific antigen ≥ 20 ng/mL
• Gleason score 8-10
• Clinical stage T3a or higher; imaging can be used to determine T stage if there is macroscopic (gross) extraprostatic extension or invasion of the seminal vesicles or other non-prostate organs
• No evidence of distant metastasis, confirmed by:
• a. Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) or equivalent staging imaging
• Planning to receive definitive external beam radiotherapy and hormone therapy as standard of care (on label or medically accepted) treatment
• Eastern Cooperative Oncology Group performance status 0-1.
• Age ≥ 18 years.
• Willingness to use adequate contraception if sexually active and of reproductive potential
• Ability to understand and willingness to sign informed consent.
• Stated willingness to comply with all study procedures and availability for the duration of the study.

You cannot join if

• Evidence of metastatic disease, including nodal disease beyond the pelvis or distant metastases on imaging.
• Clear evidence of regional nodal disease on conventional imaging.
• Prior prostatectomy.
• Prior systemic therapy for prostate cancer, including:
• Androgen deprivation therapy (Note that participants who have started Androgen deprivation therapy within 90 days prior to randomization can be enrolled.)
• Androgen receptor pathway inhibitor (e.g., abiraterone, enzalutamide, apalutamide, darolutamide).
• Chemotherapy for prostate cancer.
• Prior pelvic radiotherapy.
• Any condition that, in the investigator's judgment, would compromise the patient's safety or compliance.

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

Treatments listed in the registry

• Radiation therapy (Radiation): Radiotherapy with short-term androgen deprivation therapy plus, if indicated, an androgen receptor pathway inhibitor.

Randomized · Parallel · masking: None

As the registry describes them. Requirements to join, such as a tissue sample, are in the eligibility list above even when on-study procedures are optional. Ask the study team which steps apply to you.

• biopsy: Part of the study plan
• questionnaires: Part of the study plan
• radiation: Part of the study plan; some time points described as optional

Main goals

• Failure-free survival (Within 5 years)

Planned enrollment: 150 (estimated).

• University of California San Diego, La Jolla, California

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT07364071

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Aug 3, 2026. Public record; not medical advice.